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Abstract
Background: The aim of the SPHERE study is to design, implement and evaluate tailored practice
and personal care plans to improve the process of care and objective clinical outcomes for patients
with established coronary heart disease (CHD) in general practice across two different health
systems on the island of Ireland.
CHD is a common cause of death and a significant cause of morbidity in Ireland. Secondary
prevention has been recommended as a key strategy for reducing levels of CHD mortality and
general practice has been highlighted as an ideal setting for secondary prevention initiatives.
Current indications suggest that there is considerable room for improvement in the provision of
secondary prevention for patients with established heart disease on the island of Ireland. The
review literature recommends structured programmes with continued support and follow-up of
patients; the provision of training, tailored to practice needs of access to evidence of effectiveness
of secondary prevention; structured recall programmes that also take account of individual practice
needs; and patient-centred consultations accompanied by attention to disease management
guidelines.
Methods: SPHERE is a cluster randomised controlled trial, with practice-level randomisation to
intervention and control groups, recruiting 960 patients from 48 practices in three study centres
(Belfast, Dublin and Galway). Primary outcomes are blood pressure, total cholesterol, physical and
mental health status (SF-12) and hospital re-admissions.
The intervention takes place over two years and data is collected at baseline, one-year and two-
year follow-up. Data is obtained from medical charts, consultations with practitioners, and patient
postal questionnaires.
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The SPHERE intervention involves the implementation of a structured systematic programme of 
care for patients with CHD attending general practice. It is a multi-faceted intervention that has 
been developed to respond to barriers and solutions to optimal secondary prevention identified in 
preliminary qualitative research with practitioners and patients. General practitioners and practice 
nurses attend training sessions in facilitating behaviour change and medication prescribing 
guidelines for secondary prevention of CHD. Patients are invited to attend regular four-monthly 
consultations over two years, during which targets and goals for secondary prevention are set and 
reviewed. The analysis will be strengthened by economic, policy and qualitative components.
Background
Coronary heart disease (CHD) is a common cause of
death and an important cause of morbidity in Ireland.
Secondary prevention of heart disease involves long-term
management of risk factors among people who have been
diagnosed with established CHD. The Scottish Intercol-
legiate Guidelines Network has defined secondary preven-
tion as the 'identification and modification of risk factors
by the introduction of lifestyle measures and pharmaco-
logical therapy and cardiac rehabilitation' [1]. Secondary
prevention has been recommended as a key strategy for
reducing levels of CHD [2,3]. Secondary prevention can
be achieved by stopping smoking, making healthier food
choices (including reducing fat intake and increasing
intake of fruit, vegetables and fibre), becoming physically
active, achieving an ideal weight, consuming alcohol in
moderation, appropriate prescription of, and adherence
to, pharmacological therapy, achieving blood pressure
level at or under 140/90 mmHg and achieving a total cho-
lesterol level at or below 5 mmol/l [3].
Most people with CHD regularly attend their general prac-
titioner and general practice has been highlighted as an
ideal setting for secondary prevention initiatives [2]. Pre-
vious studies of provision of secondary prevention in gen-
eral practice have identified sub-optimal levels [4-6].
Current indications suggest that there is considerable
room for improvement in the provision of secondary pre-
vention for patients with established heart disease on the
island of Ireland [7]. Recent data from the national Heart-
watch programme suggest that 44% of Irish patients with
established heart disease have a systolic blood pressure
above the recommended guidelines of 140 mmHg, and
that 36% have a baseline cholesterol level of greater than
5 mmol/l (Leahy J, personal communication). In a survey
of secondary preventive care of 1,600 patients, from 35
randomly selected general practices in the west of Ireland,
results were as follows: 23% of patients were regular
smokers, 45% had cholesterol readings greater than 5
mmol/l and 34% had blood pressure readings greater
than 140/90 mmHg. In addition, GP records were found
to be incomplete, with 38% of patients with no record of
smoking status and 25% with no cholesterol reading.
Information from Northern Ireland suggests a similar sit-
uation: a recent survey found that among patients with a
confirmed diagnosis of CHD 18% smoked, 25% had a
body mass index (BMI) greater than 30, 51% had a systo-
lic blood pressure greater than 140 mmHg and approxi-
mately 50% had cholesterol levels greater than 5 mmol/l
[8].
Randomised controlled trials have investigated the effec-
tiveness of secondary prevention interventions including
health visitor advice [9], nurse-led secondary prevention
clinics [10,11], outreach visits to practices by nurses
trained in cardiovascular risk factor recording [12], provi-
sion of specialist liaison nurses to bridge the gap between
secondary and primary care [13], postal prompts to
patients to encourage lifestyle changes [14], audit and sys-
tematic recall of patients from disease registers [15], com-
bined training to all practice staff in information systems
and evidence-based medicine [16] and a cognitive-behav-
ioural disease management programme [17].
These trials have reported a number of successful out-
comes, including increased physical activity [9,10,17],
improved diet [9,10,17], increased health functioning
[9,10,17], increased patient assessment and recording of
risk factors [12,14-16], increased rate of consultation for
coronary heart disease [14], improvements in medication
prescribing [10,15], improved lipid management
[10,14,16], reduction in cholesterol level [16], improved
blood pressure management [10], increased lifestyle
advice provision [14] and reduced anxiety and depression
[17].
However, with the exception of the PIER trial [16] which
achieved significant reductions in cholesterol levels
among intervention group patients, trials have not
achieved significant improvements in objective biophysi-
cal risk factors, such as blood pressure or cholesterol
levels.
A systematic review identified twelve randomised trials of
disease management programmes for patients with estab-
lished heart disease [18]. It concluded that such pro-
grammes do improve processes of care, reduce hospital
admissions and enhance quality of life and functional
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status in patients with CHD. However, the reviewers
noted that studies included imprecise descriptions of both
the interventions and the usual care provided to the con-
trol groups, resulting in an inability to determine the
incremental benefits of the various components of each
intervention. Reviewers concluded that several important
issues require further clarification, including the optimal
mix of interventions and the cost-effectiveness or the eco-
nomic impact of such interventions. Another earlier sys-
tematic review [19] also noted both the lack of detail
provided of complex health service interventions, espe-
cially in the description of the usual care provided to con-
trol groups, and the need for the careful design and
evaluation of different implementation models of second-
ary prevention.
Further possible explanations for the lower than expected
clinical impact of secondary prevention interventions to
date include inadequate consideration of doctors' and
patients' perspectives on heart disease, lack of patient-cen-
tredness of the intervention and a failure to tailor practice
interventions to individual patients and practices [13].
Wiles [20], utilising a qualitative approach as part of the
SHIP study, especially emphasised the failure of 'official
accounts' to acknowledge patient perceptions as a key fea-
ture in people's reluctance to adopt lifestyle change.
There is substantial evidence that structured systematic
care is important to improve levels of secondary preven-
tion of coronary heart disease, and an effective register,
recall system and routine audit of care are essential com-
ponents of such a system [13,21]. There is also some evi-
dence to suggest that nurse-led clinics [10], cognitive
behavioural interventions [17,22,23] and tailored train-
ing identified by practice staff [16] are effective in improv-
ing secondary prevention in general practice and
facilitating patients to make lifestyle changes.
A recent Cochrane review [24] of interventions to imple-
ment prevention in primary care highlighted the need to
tailor interventions to address specific barriers to change
in a particular setting. The review also concluded that
multi-faceted interventions may be more effective than
single interventions, as more barriers to change can be
addressed. The authors of the review recommend that
future research should analyse barriers to change and
report interventions to implement preventive services in
more detail, to clarify how interventions relate to specific
barriers. Since such complex interventions are likely to be
more costly than single interventions, these reviewers also
advise that economic evaluations should be included in
future studies.
The SPHERE Study aims to take these recommendations
on board in developing an intervention to improve sec-
ondary prevention of CHD in general practice in Ireland.
The SPHERE study involves the implementation of a
structured systematic programme of care for patients with
CHD attending general practice. The SPHERE interven-
tion is multi-faceted and has been developed to respond
to the barriers and solutions to optimal secondary preven-
tion identified in preliminary qualitative research with
practitioners and patients. The delivery of the intervention
is tailored as much as possible to the needs of practices
and patients. The process of the intervention will be doc-
umented and described in sufficient detail to allow repli-
cation of the intervention and to enable identification of
effective intervention components. The intervention will
be implemented over a 24 month period, with data collec-
tion at baseline, 12 months and 24 months. Data collec-
tion at these time points will enable identification of any
initial and/or sustained changes effected by the interven-
tion. An economic evaluation of the intervention will be
carried out. The implementation of the intervention will
be monitored throughout the duration of the trial and
documented.
In summary, SPHERE will add to what is already known
in respect of secondary prevention in primary care, i.e.
• that structured programmes, with continued support
and follow-up of patients, help improve recording of
process measures of preventive care, patients' functional
status, quality of life and lifestyle change [9-11,15,17,25].
• prompts to patients improve their attendance but there
is no associated change in measures of risk [13,15].
• structured recall programmes which do not take account
of individual practice needs improve recording but not
prescribing [15]; provision of training, tailored to practice
needs of access to evidence of effectiveness of secondary
prevention is associated with improved prescribing [16]
• patient centred consultations impact positively on
health outcomes [26] but must be accompanied by atten-
tion to disease management guidelines to achieve clinical
objectives [27].
SPHERE will:
• record organisational detail of care, in both intervention
and control practices
• provide information and training tailored to practices'
needs for delivery of secondary prevention
• support patient centred consultations and practitioners'
adherence to disease management guidelines.
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Aim
To design, implement and test tailored practice and per-
sonal care plans to improve the process of care and objec-
tive clinical outcomes for patients with established
coronary heart disease in general practice in Ireland.
Design
Cluster randomised controlled trial, with practice-level
randomisation to intervention and control groups.
Random Selection of Practices and Patients
Practice identification (48 practices, 16 at each centre)
The same method is followed by each centre in Belfast,
Dublin and Galway for their respective regions of the East-
ern Health and Social Services Board, the South Western
Area Health Board and the Western and North Western
Health Boards.
Lists of all practices meeting eligibility criteria are gener-
ated by the research nurses in each centre (see 'practice eli-
gibility' section below for criteria). Practices are then
allocated a number and randomly selected from the lists
in each region by an individual independent of the
research team using computer-generated random num-
bers. The practice manager or lead general practitioner in
each practice is contacted by telephone by the research
nurse to determine their interest in receiving information
about the trial. With their agreement, information is
posted to the practice (see additional file 1: Appendix A)
and arrangements are made for a member of the research
team to visit the practice to discuss their participation in
the study.
During this meeting the research nurse explains the study
to practice staff and gets commitment to the study, indi-
cated by a signature, from practice staff (at least one GP,
one practice nurse and one administrator). A Practice
Implementation Plan is completed (see additional file 1:
Appendix A) and all practice staff are invited to review and
approve it. Practices that agree to participate are offered an
honorarium of €1000 or the Sterling equivalent upon
completion of the study.
If selected practices decline to participate or confirm that
they do not meet the eligibility criteria, the next practice
on the list is selected. Relevant details (number of whole-
time equivalent (WTE) practitioners, list size and reason
for not being recruited or not agreeing to participate) are
recorded for those practices which are not recruited.
Patient identification (20 patients in each practice)
Participating practices compile a list of all eligible patients
(see 'patient eligibility' section below for detail) from
their practice and allocate a number to each patient from
1 to Y (where Y is the total number of patients on the list).
Research nurses assist the practices in using a list of ran-
dom numbers to select patients for participation (see
additional file 1: Appendix A). A confidentiality agree-
ment will be signed between research nurses and practice
staff, to ensure that normal ethical procedures governing
each practice are adhered to. Selected patients are posted
an invitation letter, information sheet and reply slip (see
additional file 2: Appendix B) as well as a questionnaire
(see additional file 3: Appendix C). Patients who do not
respond within ten days are contacted by a member of the
practice staff to ascertain interest in participation. If
selected patients do not confirm that they fulfil the eligi-
bility criteria or decline to participate, the next patient on
the list is selected until the quota of 20 is reached. The age,
gender and diagnostic inclusion criteria for those who do
not participate are recorded. Patients who agree to partic-
ipate are invited to attend the practice for a baseline data
collection consultation.
Once sixteen practices have been recruited and the rele-
vant patient baseline data collected, at each centre an indi-
vidual independent of the research team using computer-
generated random numbers will allocate, with prior strat-
ification, practices to intervention or control groups. Strat-
ification will be according to the WTE for practitioners
(less-than-two and two-or-more). Patient identification
and baseline data collection occur prior to practice ran-
domisation to minimize potential bias introduced by
researchers and practitioners being aware of their alloca-
tion to either the intervention or control group. For inter-
vention practices, meetings will be arranged to develop
tailored practice care plans, deliver appropriate training,
and support practitioners in reviewing patients four
monthly for two years. Control practices will be visited
again after one year and after two years, at which time
points follow-up data will be collected.
Practice and Patient Selection: Inclusion and 
Exclusion Criteria
Practice eligibility
Practices are eligible to take part if they:
• Have a practice nurse, involved in general patient care
(to be confirmed at the initial practice visit).
• Did not participate in the pilot phase of the study.
For practices in the Republic of Ireland
• Are not participating in Heartwatch (a national pilot
programme in the Republic of Ireland on the provision of
secondary care in general practice, currently ongoing).
• Have a minimum General Medical Scheme (GMS) list
size of 700 patients. Based on an Irish prevalence rate of
3.16% for CVD [7], this will ensure at least 22 eligible
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GMS patients per practice, a figure which will be supple-
mented by non-GMS patients.
For practices in the North of Ireland
• Have a minimum NHS list size of 1800 patients. Based
on a UK prevalence rate of 2.6% for CVD [4], this will
ensure at least 40 eligible patients per practice.
Patient eligibility
Inclusion criteria
Patients with existing cardiovascular disease (defined as:
documented MI, CABG or angioplasty, or a diagnosis of
angina – confirmed by exercise stress test, isotope test or
coronary angiogram) are eligible for inclusion.
Exclusion criteria
Patients with significant mental or physical illness (based
on the recorded judgement of practice staff), which is
likely to impair capacity to change lifestyle behaviour or
assimilate new information, are not included.
Sample Size Calculation
The study aims to achieve a final sample of 635 patients
from at least 42 practices (see Figure 1).
Sample size calculations are based on the following:
• Power of 80% and alpha of 5%.
• Only patients agreeing to participate in the study and
completing baseline data collection will be entered into
the study. There will, therefore, be 100% uptake at the
start of the study. Reasons for non-participation will be
documented and recorded, and participation rates will
provide a measure of the acceptability of this type of inter-
vention to patients.
• A final completion rate of 70% is anticipated based on
similar studies in the West of Ireland 7 (completion rate =
68.7%) and Dublin [28] (completion rate = 93%).
• Practice attrition of 12.5% has been allowed for (though
practice attrition in another similar study was only 4%
[28]).
• Improvements in the control group as a result of partic-
ipation in a research study have been anticipated [25].
• Design effects are calculated using intracluster correla-
tion coefficients from data from similar populations in
Galway and Scotland (Campbell N, personal
communication).
A total sample size of 907 patients recruited from 46 prac-
tices gives a varying but minimum power of 80% to detect
significant changes in proportions with poor blood pres-
sure and cholesterol control, physical and mental well
being (SF-12) and hospital readmissions at two years.
(Detailed power calculations are given below). This
allows for a final patient follow-up and retention rate of
70% and a practice attrition rate of 10%. The number of
practices is rounded up from 46 to 48, to allow equal
numbers of practices to be recruited in each of the three
study centres. Sixteen practices will therefore be recruited
in each of the three centres, eight intervention practices
and eight control practices. Twenty patients are recruited
in each practice. Final data analysis will incorporate mod-
elling techniques that are more statistically efficient and
will ensure greater power to detect significant changes in
study outcomes.
Power Calculations – Further Detail
Blood pressure
44% of Irish patients with established heart disease have
a systolic blood pressure above recommended guidelines
(SBP >140 mmHg) (Leahy J, personal communication).
Previous research indicates that an improvement of 20%
can be anticipated in the control group [10]. Taking this
into consideration, a sample size of 408 gives 80% power
to detect a 50% reduction in the proportion of patients
with a SBP above 140 mmHg (i.e. giving a proportion of
22%) in the intervention group with a corresponding
20% improvement in the control group. Other studies
Flow of Practices and Patients Throughout Trialigure 1
Flow of Practices and Patients Throughout Trial.
24 practices
receive intervention:
454 participants
21 practices at
1 year and 2 year 
follow-up:
318 participants
30% patient 
non-response.
Practice attrition
rate of 3 
30% patient 
non-response.
Practice attrition
rate of 3 
21 practices at
1 year and 2 year 
follow-up:
317 participants
Randomisation
24 practices
in control group:
453 participants
48 practices
consent to participate
XX practices 
assessed for eligibility
Excluded: XX
practices ineligible/
refuse to participate
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have indicated that it is possible to achieve similar targets
in general practice populations with established coronary
heart disease [15]. To take account of cluster randomisa-
tion, based on recruiting 15 patients per cluster, a design
effect size of 1.15 and an intracluster correlation coeffi-
cient of 0.011 [4,10] suggests a sample size of 470 patients
from 31 practices. Allowing for a final response rate of
70% and a practice attrition rate of 10% requires recruit-
ment of 670 patients from 34 practices.
Cholesterol
36% of Irish patients have a baseline cholesterol level
above the upper recommended limit, i.e. greater than 5
mmol/l (Leahy J, personal communication). To demon-
strate an improvement of 50% in the intervention group
and 20% in the control group requires a sample size of
500 patients. To ensure a final sample of 15 patients per
practice, this is inflated by a design effect size of 1.27 (ICC
= 0.019; Campbell N, personal communication) to give a
sample of 635 patients from 42 practices. This is increased
to 907 patients from 46 practices to allow for final follow
up and response rate of 70% and practice attrition of 10%.
SF-12
A 5 point improvement in the SF-36 has been found to be
clinically significant [29]. Based on a mean at baseline of
53.98 (SD 8.39) [7], a sample size of 120 patients is
sufficient to detect a clinically significant improvement of
5 points in the SF-12 measure of physical and mental
health status in the intervention group. The intracluster
correlation coefficient from previous data [7] is <0.0001,
indicating that there is no clustering effect for this variable
and that the design effect size is 0. Allowing for a patient
retention rate of 70% and a 10% practice attrition rate,
170 patients from 10 practices are needed.
Hospital re-admissions
Northern data (Cupples M, personal communication)
indicates that 43% of control patients had hospital admis-
sions in two years. To reduce this by 50% in the interven-
tion group and 20% in the control group needs a sample
size of 356 patients. To ensure a final sample of 15
patients per practice, this is inflated by a design effect size
of 1.08 (ICC = 0.006) to give a sample of 406 patients
from 27 practices, increased to 580 patients from 30
practices to allow for final follow up and response rate of
70% and practice attrition of 10%.
The study acknowledges that smoking is a significant risk
factor for cardiovascular disease. For pragmatic reasons
smoking has not been used to power the study, as levels
of smoking have become low among this population and
its measurement would require a sample size too large for
the resources available.
Intervention
Level 1: Tailored practice care plans
(1) Training for practice staff
Training will be delivered independently in each of the
three regional study centres. All trainers will adhere to a
single training protocol to ensure standardised delivery of
the training across centres. Training delivery will be
planned and rehearsed jointly by all trainers using role-
play and peer review techniques. In addition, the project
manager will act as an observer during the first two train-
ing sessions in each centre and will provide feedback to
trainers with a view to further standardizing the training.
The Irish College of General Practitioners (in the Republic
of Ireland) and the Northern Ireland Medical and Dental
Training Agency (in Northern Ireland) have approved the
proposed training sessions for their educational contribu-
tion to practitioners' personal development plans.
First training session: Medication training
GPs and practice nurses are invited to attend a ninety-
minute training session on medication guidelines, deliv-
ered by the study GP in each region:
• Belfast: Dr. Margaret Cupples, Department of General
Practice, Queen's University Belfast.
• Dublin: Dr. Susan Smith, Department of Public Health
and Primary Care, Trinity College Dublin.
• Galway: Professor Andrew Murphy, Department of Gen-
eral Practice, NUI Galway.
This is an interactive session in which practice staff are
invited to review and discuss the most recent medication
prescribing guidelines for secondary prevention. The ses-
sion uses case-based scenarios to enable the practitioners
to reflect on their own practice. Practitioners are offered a
summary sheet of prescribing guidelines and a summary
'prompt' showing commonly used drugs and dosages
within the various medication categories. If practices wish
their practice nurse to make prescribing decisions the
research nurse will help to prepare appropriate specific
protocols.
The objectives of this session are:
• To increase confidence and competence regarding pre-
scribing and the secondary prevention of heart disease.
• To discuss the role of the SIGN guidelines and apply to
real clinical situations.
• To explore practitioner attitudes to secondary preven-
tion and to discuss points raised specifically by each
practice.
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• To address issues of patient adherence to medication.
Second training session: Behaviour change training
GPs and practice nurses are invited to attend a ninety-
minute training session on facilitating patients with
behaviour change, delivered by the research nurse in each
region. This is an interactive session in which practice staff
are invited to reflect on their views around lifestyle change
and practice new techniques (through role play) to
improve their ability to facilitate patients with behaviour
change. Strategies to increase patient motivation are dis-
cussed, following guidelines from brief motivational
interviewing literature [30,31]. Additional techniques,
based on principles of behaviour modification and social
learning theory [32], include: setting small achievable
goals, action planning, using prompts, self-monitoring,
offering rewards, habit reinforcement, and relapse
prevention.
The objectives of this session are:
• To enable practitioners to develop skills based on lead-
ing behaviour change theories, which may help them with
behaviour change consultations.
• To introduce the SPHERE patient-held booklet and the
patient care plan (see 'Level 2' below).
(2) Responding to individual practice needs
Additional practice needs in relation to the delivery of pre-
ventive care for patients with established cardiovascular
disease, as well as the day-to day running of the study, are
recorded on a tailored practice care plan and followed up
by the SPHERE research nurse.
(3) Ongoing support from the SPHERE research nurse
The SPHERE research nurse maintains regular contact
with the practices, and is easily contactable by phone if
practice staff have any queries about SPHERE.
(4) SPHERE newsletter
Intervention practices receive a study newsletter which is
published every four months. The newsletter contains the
latest news and updates relating to the study.
Level 2: Tailored patient care plans
(1) Initial target setting consultations
The first patient intervention consultation with the GP/
practice nurse takes place as soon as possible after base-
line data collection, once training of practice staff has
been completed. BP and BMI are measured, diet, smoking
and exercise habits reviewed and the result of the baseline
cholesterol assay discussed. The patient and practitioner
together identify areas of management which could be
improved and the patient is invited to prioritise one par-
ticular aspect of their lifestyle for change. Possible ways of
achieving targets reflecting optimal management (BP
<140/90 mmHg, cholesterol <5 mmol/l, BMI <25, non-
smoking, taking exercise for 30 minutes 5 days per week,
eating fruit/vegetables daily and avoiding saturated fat
intake, avoidance of stress) are identified. Plans for action
are recorded on a personal care plan tailored for each
patient and retained in the practice. The GP may also see
the patient at this visit or at a further appointment within
2 weeks to determine if any change in medication is
appropriate. A further follow up telephone call is made by
the practice nurse to give support and address any ques-
tions 2 weeks later.
(2) The patient-held booklet
This booklet contains information on all the key risk fac-
tors for CHD. It is used by the practitioners in all initial
target setting discussions with the patient and is given to
the patient to be kept by them. The booklet can be referred
to at subsequent consultations with the GP or practice
nurse for consolidation of information relevant to sec-
ondary prevention and cardiovascular risk. There are 6
sections in the book:
a) Medications
b) Smoking
c) Exercise
d) Healthy eating
e) Stress
f) Community support
By providing a summary of lifestyle advice for secondary
prevention of CHD, the booklet serves not only as an
information resource for patients but also as a reference
guide to help practitioners in their lifestyle-related consul-
tations with patients.
(3) Regular consultations with patients for two years
Patients are invited to attend for an appointment with the
GP/nurse every 4 months. At each visit a review of factors
relating to targets and goals for optimal secondary preven-
tion are made as appropriate. Goals relating to diet, smok-
ing and exercise habits are routinely reviewed. Cholesterol
is checked if it has been found to be raised at baseline, but
if normal at baseline cholesterol is checked annually. Rel-
evant measurements taken at each review visit are
recorded and held in the practice and reviewed with the
patient at subsequent review visits. Care which would be
given according to current clinical guidelines will also be
provided, as required.
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Control Practices
Data are collected for patients in intervention and control
practices in identical ways. In control practices, data are
collected at baseline, one and two years post baseline.
Otherwise, patients in control practices continue to
receive health care as usual and the nature of this in each
participating practice will be clearly described.
Informed Consent
An information sheet is sent to all potentially eligible
patients (see additional file 2: Appendix B). Patients are
asked to sign and return, with their postal questionnaire,
a reply slip (see additional file 2: Appendix B) to allow fur-
ther contact regarding the research. At their first consulta-
tion for baseline data collection, the GP/practice nurse
ensures their understanding of the study, allows them the
opportunity to ask questions and confirms their willing-
ness to participate in the study before asking them to sign
a consent form (see additional file 2: Appendix B).
Ethical Approval
Ethical approval has been granted by the Ethics Commit-
tee of the Irish College of General Practitioners and the
Queen's University Research Ethics Committee.
Data Collection
Data collection will involve three components:
• Questionnaire posted to patient from the practice with
administrative assistance from the SPHERE research
nurse. Questionnaire is posted back to the practice in a
pre-paid envelope. The research nurses liaise with practice
staff to follow up non-responders.
• Consultation data gathered by practice staff and
inserted into one page SPHERE study baseline measure-
ment record.
• Chart search to establish process of care and collect
patient outcomes recorded in GP records. This is carried
out by research nurse (after obtaining patient consent),
and recorded onto SPHERE study database.
The above data will be collected at three time points:
1) Baseline
2) One year
3) Two years.
Data are collected at one year to assess the initial effects of
the intervention. No results of any interim analyses will be
revealed to any member of the research team unless the
Data Monitoring Committee (see below) determine that
it is unethical to continue the study.
Data to be collected are described below.
Questionnaire components (see additional file 3:
Appendix C)
A. Physical and mental well-being: SF-12.
B. Exercise: Godin Leisure-Time Exercise Questionnaire.
C. Smoking status: adapted from SLÁN study [33].
D. Diet: DINE, including question regarding portions of
fresh fruit and vegetables.
E. Personal and demographic variables:
a. Demographics: name, date of birth, marital status, edu-
cational level, occupation, GMS eligibility (for practices in
the Republic of Ireland).
b. Economic analysis questions: journey time to GP and
hospital.
c. Health service attendance in previous 12 months:
including hospital outpatient services, admission to hos-
pital as an inpatient, visits to Accident and Emergency
department and days spent as inpatient.
F. Adherence to medication: Medication Adherence
Report Scale MARS-5.
Consultation/physical assessment components (taken
by practice nurse/GP) (see additional file 4: Appendix D)
1. Blood pressure.
2. Total serum cholesterol concentration (HDL and LDL).
3. Current medications, dose and contraindications.
4. Height in cm/weight in kg/BMI/waist circumference in
cm/waist hip ratio.
Chart search data (collected by SPHERE research nurse)
(see additional file 4: Appendix D)
1. Cardiac history: months since diagnosed with CHD,
record of myocardial infarction and time since myocardial
infarction, presence of angina, investigation confirming
diagnosis, previous PTCA or CABG, presence of diabetes.
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2. Number of GP and practice nurse consultations in last
12 months.
3. Number of attendances at outpatients/inpatient serv-
ices in last 12 months.
4. Recording of risk factors in medical records: smoking,
cholesterol and blood pressure.
Data Analysis
Description of study participants
Practices and patients participating in the SPHERE study
will be heterogeneous. Participating practices will be
described in terms of:
• Number and gender of full time equivalent GPs
• Number of practice nurses
• Numbers of support staff
• Practice list size – in the Republic of Ireland this will be
presented as GMS list size and estimated non-GMS list.
Participating patients will be described in terms of:
• Age
• Gender
• Disease duration
• Nature of cardiovascular disease:
Angina
MI
• Procedures:
Angioplasty
CABG
• Socioeconomic status (according to occupation).
Randomised controlled trial analysis
Primary outcomes include:
• Blood pressure
• Total cholesterol
• Physical and mental status as measured by the SF-12
• Hospital re-admissions.
Secondary outcomes include:
• Measure of the process of care
SPHERE visits
Total number of GP visits
Total number of hospital OPD visits
Recording of risk factors in GP records
• Body Mass Index/Waist-Hip Ratio
• Exercise: Godin Leisure-Time Exercise Questionnaire
• Smoking status
• Diet: DINE, including question regarding portions of
fresh fruit and vegetables
• Adherence to medication (Medication Adherence
Report Scale MARS-5).
All results are analysed using SPSS and Stata statistical
software. Statistical modelling is carried out using Stata
statistical software which has a facility for complex survey
sample analysis that allows for adjustments in data analy-
sis based on design effects, planned or unplanned. Statis-
tical significance will be taken at the 5% level for both
primary and secondary outcomes. The analysis examines
intervention vs control groups on study completion, as
opposed to looking at changes in the intervention and
control groups from baseline.
Sub-group analyses
Sub-group analyses will be carried out on the following
groups:
• Angina only vs other diagnoses
• CABG vs angioplasty
• Diabetes vs non-diabetes
• Men vs women
• Northern Ireland vs Republic of Ireland
• Patients < 70 years vs older.
Analyses will be carried out using two approaches:
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• By intention to treat i.e. including all randomised
patients, regardless of their participation in the
intervention.
• Sensitivity analyses will explore whether adherence to
the intervention influences the effect of the intervention
on primary outcomes.
Data management
The project manager has primary responsibility for the
maintenance and management of the study database,
which will be stored on a password-protected computer in
a locked office. Research nurses have responsibility for
ensuring the completeness, accuracy and confidential
storage of data collected in their respective region from
patient questionnaires, during the data collection consul-
tations and from patient charts. Each practice and patient
participating in the study has a unique identifying code.
Data will be collected and processed in the following
ways:
1. Questionnaire data: once received in the practice, the
research nurse collects the questionnaires and inputs the
data into a master SPSS study database. Questionnaires
are stored securely in their regional research centre.
2. Consultation data: once complete, the research nurse
collects the data collection sheets from the practice and
inputs the data into the master SPSS database. Data collec-
tion sheets are stored securely in their regional research
centre.
3. Chart search data: the research nurse enters this data
directly from patient notes onto an electronic study data-
base created in Filemaker Pro software. Data can subse-
quently be exported directly into the master SPSS database
using the unique patient identifier as the link field.
In the interests of data accuracy, numerical fields have
range limiters to ensure that values outside a particular
range cannot be entered; also, random data checks are per-
formed on a regular basis to confirm completeness and
accuracy of data. Inter-researcher data entry reliability is
ensured by a process of trial data entry by the three
research nurses of a sample of 20 questionnaires and con-
sultation data sheets and 10 patient charts data early in
the study data collection process. Where discrepancies in
data entry are observed between the researchers, discus-
sion will ensue to resolve any ambiguities or disagreement
and clarify data collection and entry guidelines. Once all
data has been completely entered and checked in the mas-
ter SPSS database, preliminary analysis can be performed.
The data will be sent in this format to the study statisti-
cian, who will import the data into Stata software to per-
form the necessary statistical modelling procedures.
Data monitoring
Interim results after one year will be presented to an inde-
pendent data monitoring committee (DMC), made up of
a statistician, an epidemiologist, and a clinician with sta-
tistical expertise. The role of the DMC will be to:
a) Ensure that no harm is being conducted to study
participants
b) Act in an advisory capacity with respect to research
governance.
Qualitative Evaluation
Introduction
Qualitative research will be conducted after years 1 and 2
of the intervention. It will facilitate evaluation of the inter-
vention based on the experiences of practice staff and
patients in delivering and receiving the intervention
respectively. It also aims to compare their experiences
with those of patients and practitioners in the control
practices. The qualitative research will be integrated with
the economic and policy evaluations.
Aims for intervention group (Year 1)
The aims of the qualitative evaluation study with the
intervention group at the end of year 1 are to explore:
• How the intervention is implemented
• How the intervention is integrated with other practice
activities
• How well practitioners and patients understand the
intervention
• Whether elements of the intervention are particularly
important or problematic
• Attitudes to the cost of implementing the intervention
for practices and patients.
Aims for control group (Year 1)
The aims of the qualitative evaluation study with the con-
trol group at the end of year 1 are to explore:
• The nature of secondary prevention care implemented
during the study period
• The impact of any policy changes during that time.
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Aims for intervention group (Year 2)
The aims of the qualitative evaluation study with the
intervention group at the end of year 2 are to explore:
• Changes in how the intervention is implemented and
the reasons why
• Whether the aims of the intervention have been
achieved
• The feasibility of the intervention being continued after
the study ends
• Whether patients would be willing to pay for such a
service.
Aims for control group (Year 2)
The aims of the qualitative evaluation study with the con-
trol group at the end of year 2 are to explore:
• Changes in how secondary prevention care is imple-
mented and the reasons why
• The impact of any policy changes during that time.
Data collection and analysis
The qualitative research will be guided by the principles of
the methodology of grounded theory. Practitioners and
patients will be purposively sampled using theoretical and
maximum variation sampling methods to ensure a variety
of characteristics and experiences. Small and large prac-
tices that reflect a mixture of rural, urban, deprived and
affluent locations will be selected.
The data will be collected using focus groups and individ-
ual semi-structured interviews. The focus groups aim to
explore the diverse experiences of patients receiving the
intervention. They will include men and women who vary
in the nature of their heart disease, length of time since
diagnosis, age and ethnic group (if possible). Participants
will be invited to participate by letter which will explain
the purpose of the interviews, followed by a telephone call
from the practice nurse. Their reasons for not wishing to
participate in the interviews will be recorded. The research
nurses will act as observers of the focus group and will
take notes of the discussion and map the interaction of the
participants. Individual interviews with some patients will
be used to clarify and to explore in more detail issues dis-
cussed in the focus groups. Free text comments in the
patient questionnaire that forms part of the economic
evaluation will also form part of the qualitative
evaluation.
Individual interviews will also be conducted with GPs and
practice nurses who are involved in implementing the
intervention, with more interviews being conducted with
the nurses, who tend to be responsible for the clinics. The
interviews and focus groups will be audio-taped with the
participants' consent and transcribed verbatim.
The interviews and focus groups will be divided between
two qualitative researchers. The development of an inter-
view schedule and role plays of the interviews by the
researchers will be used to standardise the interviews and
minimise the effects of the researchers on the data.
Data on the actual process of care will also be collected
using overt observation methods by the research nurses.
This will strengthen the validity of the interview data by
comparing what practitioners actually do with what they
say they do and will act as a quality control measure. Field
notes of the research nurses' observations of the interven-
tion based on their regular contacts with the practices will
also form part of the qualitative data. These will be
explored in more detail in a focus group with the research
nurses.
The control practices will act as negative cases and will test
whether the data from the intervention practices are
unique to them or are shared with non-intervention prac-
tices. This will strengthen the reliability of the data from
the intervention practices. The characteristics of the partic-
ipants will be matched to the characteristics of partici-
pants in the intervention practices.
The data collection and analysis will be iterative and will
continue until data saturation is achieved. Analysis will be
conducted using the constant comparative method and
will be facilitated by importing the interview transcripts
into the computer software programme Nudist. A sum-
mary of the main findings will be sent to a sub-sample of
patients and practitioners from the intervention and con-
trol groups in each of the 3 centres who were interviewed
to validate our findings.
The number of interviews will be divided equally among
the 3 centres. The number of interviews to be conducted
among patients and practitioners is shown in Tables 1 and
2.
Economic Evaluation
Introduction
The economic analysis incorporates both cost minimiza-
tion analysis and cost effectiveness analysis for the various
interventions for the two groups. The basic tasks of the
evaluation are to identify, measure, value and compare
the costs and outcomes of the alternatives being consid-
ered. Costs are likely to fall on patients, their families and
the state. The health care resources consumed will reflect
the costs of organising and operating the two
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programmes: intervention and control. These costs will
reflect the time input of health professionals and fixed or
overhead costs, including any new equipment and capital
expenditure. All contacts with the health services are
recorded and valued, including general practice contacts,
hospital attendances, admissions and drug prescriptions.
The patient and family costs include any out-of-pocket
expenses and any own time input into the treatment proc-
ess. Estimates will be made of work and leisure time fore-
gone as part of the treatment alternatives, together with
quality of life estimates. Cost-effectiveness analysis is the
primary method of economic evaluation with measures of
effectiveness taken from the range of primary and second-
ary outcomes being considered for the two groups.
In the Republic of Ireland, free healthcare is available to
patients who qualify under the means-tested General
Medical Scheme (GMS), although chronic disease man-
agement is not fully supported by this system. Non-GMS
patients are required to pay for all of their own healthcare
costs. In order that the findings of the SPHERE study will
be translatable into practice within the existing healthcare
systems, non-GMS patients in the Republic of Ireland will
be required to pay for SPHERE-related visits to their gen-
eral practice as normal. The cost of extra visits by GMS
patients will be borne by the practices. The research team
acknowledges that this may have an impact on recruit-
ment of both practices and patients, although in a similar
study the impact on patient recruitment was not substan-
tial [28].
Aim
The aim of the economic analysis is to provide both cost
minimization analysis and cost-effectiveness analysis of
secondary prevention of heart disease in general practice.
The cost effectiveness analysis provides information on
the marginal costs and effects of the intervention relative
to the alternative through the calculation of an incremen-
tal cost-effectiveness ratio. In situations where there is no
significant difference in effects, the use of cost minimiza-
tion analysis allows the reporting of cost differences only.
Data Collection
The following items of data are recorded to allow report-
ing of health services costs:
• Number of visits to GP in last 12 months. It was decided
not to record length of consultation, but to use average
length from other research in calculations.
• Number of visits to practice nurse. As length of practice
nurse consultations vary, an average consultation length
will be estimated by research nurses during quality con-
trol visits.
• Use of hospital services: (1) Number of attendances to
outpatients in last year; (2) Number of days spent as
Table 1: Qualitative Research with Intervention Groups
Focus Groups Individual Interviews
Patient Focus 
Groups
Research Nurse 
Focus Groups
Total Focus 
Groups
Patient
Interviews
Practice Nurse 
Interviews
GP Interviews Total Interviews
Year 1 3 1 4 6 6 3 15
Year 2 3 1 4 6 6 3 15
Total 6 2 8 12 12 6 30
Table 2: Qualitative Research with Control Groups
Focus Groups Individual Interviews
Patient Focus Groups Total Focus Groups Practice Nurse
Interviews
GP Interviews Total Interviews
Year 1 3 3 3 3 6
Year 2 3 3 3 3 6
Total 6 6 6 6 12
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inpatient in hospital in last year; (3) Total number of days
spent in hospital in last year; (4) Number of attendances
to A&E in last year.
• Current prescription of medications: type and dose,
using Defined Daily Dose methodology.
• The study is not in a position to record patients' use of
community services, such as physiotherapy or occupa-
tional therapy.
The following items of data are recorded to allow report-
ing of patient costs:
• Occupation data.
• Travel distance, length, mode and waiting time for visits
to the practice and the hospital.
• In the Republic of Ireland, GMS status.
• Patient-estimated additional expenditure or savings
made in the process of lifestyle change as a result of the
intervention, e.g. changes to shopping bill with changed
diet, paying for exercise facilities, giving up smoking.
The following items of data are recorded to allow report-
ing of capital costs:
• Any new equipment purchased by/for the practice to
carry out the intervention.
The following items of data are recorded to allow report-
ing of intervention costs:
• All expenses associated with the intervention, such as
cost of training, information and education materials.
Outcome measures
Both primary and secondary outcome measures are col-
lected as part of the randomised controlled trial analysis.
The cost-effectiveness analysis will be based primarily on
intermediate endpoints. However, some intermediate
endpoints, such as blood pressure, are uni-dimensional
measures and may or may not have a high correlation
with a final endpoint, such as life years gained. Hence the
need to explore the estimation of final endpoints in the
analysis, where possible, thereby allowing much greater
scope to make comparisons of cost-effectiveness with
other studies.
Analysis
The analysis will use standard economic analysis for the
calculation of costs and incremental cost-effectiveness
ratios. Unit costs will be applied to the resource use data
to calculate the various costs of care. Comparisons
between the intervention and control groups will be made
on the various primary and secondary outcomes and costs
will be assigned accordingly. The analysis will allow us to
consider whether significant differences emerge between
intervention and control groups in terms of the various
outcome measures. We will examine whether the inter-
vention is associated with overall cost increases or cost
decreases and link the cost changes to incremental gains
in effectiveness, where they exist.
Policy Evaluation
A policy analysis will be carried out in the context of the
economic analysis described above. There are relatively
few comprehensive evaluations of health policies and
even fewer that use or incorporate an experimental design
as part of the appraisal process. It is expected increasingly
that rigorous, replicable, relevant and independent
research should be available to make a contribution to
evidence-based policy [34].
A policy analysis is the process through which we identify
and evaluate policies and programmes that are intended
to lessen or resolve health, social, economic and physical
problems relative to secondary prevention of cardiovascu-
lar disease. The proposed analysis is specific to policy cir-
cumstances in Northern Ireland and the Republic of
Ireland, but its outcomes will be generalisable since these
policies are examples of a wider policy movement that has
affected other industrialised countries in similar ways.
General conclusions can be drawn from case studies as
long as data about context, processes and outcomes are
collected and this study will collect such data.
The best way to assess the implications of any policy is to
identify, quantify and value systematically the costs and
benefits of the proposed policy. In brief, the policy
appraisal process involves the following stages: defining
the policy objectives; identifying the policies or pro-
gramme options; identifying and measuring the costs and
benefits associated with each option; identifying and
assessing uncertainties; and assessing the balance between
options [35].
The 5-year research programme will provide a compara-
tive, cross-health system analytical framework with which
to investigate and to evaluate the major policies relating to
heart disease as articulated in Building Healthier Hearts [2]
and in the National Service Framework [36], respectively.
The two systems differ with respect to, for example, fund-
ing and organisational structures yet experience similar
problems such as waiting lists and staff shortages. Using
this framework, the policy analysis will begin by detailing
and critically appraising the context, nature and distribu-
tion of heart disease in each system as well as the
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consequential policies and service responses. The analysis
of documentary material and secondary data will be sup-
plemented with interviews with key 'stakeholders' in the
policy process. This part of the policy analysis will lead to,
among other things, the identification and specification
of policy goals and evaluative criteria as well as an account
of the way in which the research programme will provide
a 'test' and progress marker of policy objectives and policy
implementation. The next step in accomplishing a thor-
ough policy analysis is to describe and evaluate how the
policy in the form of the proposed secondary prevention
services in each system benefits the previously established
criteria. The experimental, quantitative data relating to
outcomes together with the conceptual, qualitative data
about organisational and implementation processes plus
the results of the economic appraisal will be analysed in
an integrative way so as to evaluate and compare compre-
hensively the policies in each system – at least at a micro-
level. This incremental, step-by-step approach plus the
iterative nature of the analytical process are important
because they improve the chances of producing a rigor-
ous, context sensitive policy analysis. The research team
individually and collectively will revise and deepen earlier
levels of analysis as new data become available and new
perspectives or interpretations emerge.
In conclusion, the comparative analytical framework will
provide important insights and lessons about the process
of policy development and implementation as well as
about the pace and degree to which the policy in practice
impacts in terms of the costs and benefits of producing
"healthier hearts".
Publications Planned
Qualitative
• A qualitative study of the provision of secondary preven-
tion care for established heart disease in general practice
in two different health systems.
• A descriptive analysis of the development of a multidis-
ciplinary intervention to improve secondary prevention
care for established heart disease in general practice.
• A qualitative study of practitioners' experiences of a ran-
domised controlled trial of a multidisciplinary interven-
tion to improve secondary prevention care for established
heart disease in general practice in two different health
systems.
• A qualitative study of patients' responses to a multidis-
ciplinary intervention to improve secondary prevention
care for established heart disease in general practice in two
different health systems.
Main trial
• A baseline study of the provision of secondary preven-
tion care for established heart disease in general practice
in two different health systems.
• A randomised controlled trial of a multi-faceted inter-
vention to improve secondary prevention of cardiovascu-
lar disease in general practice.
• Differences between large and small practices in a ran-
domised controlled trial of an intervention to improve
secondary prevention of cardiovascular disease in general
practice.
Economic analysis
• An economic analysis of an intervention to improve sec-
ondary prevention of heart disease in general practice.
Policy analysis
• A policy analysis of an intervention to improve second-
ary prevention of heart disease in general practice in two
different health systems.
Other
• The impact of the process of care on outcomes of an
intervention to improve secondary prevention of heart
disease in general practice.
• The experience of implementing a randomised control-
led trial to improve secondary prevention of heart disease
in general practice in two different health systems.
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